Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
Department of Laboratory Medicine EOLAB, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland,
Nutrients. 2020 May 9;12(5):1359. doi: 10.3390/nu12051359.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), with a clinical outcome ranging from mild to severe, including death. To date, it is unclear why some patients develop severe symptoms. Many authors have suggested the involvement of vitamin D in reducing the risk of infections; thus, we retrospectively investigated the 25-hydroxyvitamin D (25(OH)D) concentrations in plasma obtained from a cohort of patients from Switzerland. In this cohort, significantly lower 25(OH)D levels ( = 0.004) were found in PCR-positive for SARS-CoV-2 (median value 11.1 ng/mL) patients compared with negative patients (24.6 ng/mL); this was also confirmed by stratifying patients according to age >70 years. On the basis of this preliminary observation, vitamin D supplementation might be a useful measure to reduce the risk of infection. Randomized controlled trials and large population studies should be conducted to evaluate these recommendations and to confirm our preliminary observation.
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）引起 2019 年冠状病毒病（COVID-19），其临床结局从轻症到重症不等，包括死亡。迄今为止，尚不清楚为什么有些患者会出现严重症状。许多作者提出维生素 D 参与降低感染风险；因此，我们回顾性地调查了来自瑞士队列患者的血浆中 25-羟维生素 D（25(OH)D）浓度。在该队列中，与 SARS-CoV-2 PCR 阳性（中位数 11.1ng/mL）患者相比，25(OH)D 水平（=0.004）显著较低（24.6ng/mL）；根据年龄>70 岁对患者进行分层也得到了证实。基于这一初步观察，维生素 D 补充可能是降低感染风险的有用措施。应进行随机对照试验和大型人群研究，以评估这些建议并证实我们的初步观察。
